Odds ratio

Transactional demand for central bank digital currency

Retrieved on: 
Thursday, April 18, 2024
POS, Learning, CB, E41, Calibration, Financial regulation, Interest, ATM, Oesterreichische Nationalbank, Journal of Macroeconomics, Sensitivity, Diffusion, ITunes, Bank of Canada, P2P, Safety, NBER, Benchmarking, Prevalence, SPACE, Bernoulli, Journal of Monetary Economics, E42, Paper, European Parliamentary Research Service, Apollo, Environment, Political economy, COVID-19, Review of Economic Dynamics, Abramov, Loss, Working paper, Choice, Collection, Probability, Dowd, Castrén, Face, Noise, History, Restaurant, Journal of Political Economy, ECB, Policy, Diary, Model, Utility, Clutch (eggs), Canadian International Council, Journal of Financial Stability, JEL, Digital, Bias, Journal, Research, Classification, CBDC, SARS-CoV-2, ECMI, Credit, Odds ratio, Literature, European Central Bank, Mises Institute, Monetary economics, Section 5, Occupation, E47, Financial intermediary, Government, Supermarket, Friction, Finance, BIS, Love, Bart, The Economic Journal, Education, Risk, Section 4, Privacy, Section 3, Appetite, App Store (iOS/iPadOS), Human, DNB, International finance, Section 2, Leonhard Euler, Payment, Attention, Central bank, Consumer, EPRS, Habit, American Economic Review, Confidence interval, FCO, Central bank digital currency, Exercise, Letizia, Applied economics, Digital currency, Sale, Business cycle, Amazon, Community business development corporation, Control, Chart, Proxy, American Economic Journal, LN, Bank, Fintech, IMF, Analysis, Aggregation, Cryptocurrency
Key Points: 

    BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

    Retrieved on: 
    Thursday, February 29, 2024
    Oncology, Health, FDA, Other Science, Science, Pharmaceutical, Biotechnology, Acalabrutinib, BTK, Progression-free survival, Hematology, Physician, Odds ratio, CLL, BGNE, Safety, University, COVID-19, Mayo Clinic, Chronic lymphocytic leukemia, University of Washington, Associate, Patient, Survival, Rituximab, Clutch (eggs), ASCEND, Pharmaceutical industry

    The analysis suggests a progression-free survival and complete response advantage for BRUKINSA versus acalabrutinib, as well as potentially improved overall survival.

    Key Points: 
    • The analysis suggests a progression-free survival and complete response advantage for BRUKINSA versus acalabrutinib, as well as potentially improved overall survival.
    • These data will be presented during the 28th Annual International Congress on Hematologic Malignancies® in Miami from February 29 - March 3.
    • “Head-to-head randomized clinical trials are the gold standard when it comes to evaluating the potential impact of individual treatments for patients.
    • The global BRUKINSA development program includes more than 5,000 subjects enrolled to date in 29 countries and regions.

    Research Finds Robotic Assistance in Cementless Total Knee Arthroplasty Does Not Improve Revision Rates Two Years Following Surgery

    Retrieved on: 
    Monday, February 12, 2024
    SAN, Hospital, TKA, Infection, Odds ratio, Risk, Medicare, Patient, AAOS, Ageing, Failure, Research, American Academy

    SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- As the use of robotic assistance in total knee arthroplasty (TKA) has grown, there has been limited research looking at whether it improved the risk of revision.

    Key Points: 
    • SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- As the use of robotic assistance in total knee arthroplasty (TKA) has grown, there has been limited research looking at whether it improved the risk of revision.
    • New data showed that revision rates were similar in conventional and robotic-assisted cementless TKA at two years post-operatively.
    • The primary and secondary outcomes were two-year all-cause odds of revision between cementless TKA with or without robotic assistance and two-year odds of the specific indication for revision surgery.
    • A total of 9,220 cementless TKAs were identified, with 4,120 (45%) performed with robotic assistance.

    Pusan National University Researchers Decode the Link Between Smoking and Amyotrophic Lateral Sclerosis Risk

    Retrieved on: 
    Tuesday, January 30, 2024
    Woman, Assistant, Patient, Risk, ALS, Meta-analysis, Tobacco Induced Diseases, Smoking, Female, Systematic review, Pusan National University, Public, PICO, Odds ratio, Smoker, Smoking cessation, Informatics, Health informatics, Area studies, Pharmaceutical industry

    This treatment gap highlights the need to identify risk factors, particularly modifiable ones, that could potentially prevent the onset of ALS.

    Key Points: 
    • This treatment gap highlights the need to identify risk factors, particularly modifiable ones, that could potentially prevent the onset of ALS.
    • While smoking has been considered a significant risk, studies have yielded inconclusive results, failing to pinpoint the exact association.
    • Identifying smoking as a modifiable risk factor highlights the potential for mitigating the risk of developing ALS through smoking cessation.
    • Title of original paper: Association of smoking with amyotrophic lateral sclerosis: A systematic review, and meta-analysis, including dose-response analysis

    Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

    Retrieved on: 
    Thursday, January 4, 2024
    Cardiology, Hospital, Food, Survival, BID, Physician, FDA, EMA, MAA, Diabetes, Disease, Massachusetts General Hospital, NDA, Incidence, MD, Doctor of Philosophy, Therapy, Odds ratio, Diabetic cardiomyopathy, New Drug Application, European Medicines Agency, SGLT2, Patient, Safety, Galactosemia, Heart failure, Pharmaceutical industry

    NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of progression to overt heart failure.  

    Key Points: 
    • While a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant (p=0.210).
    • The ARISE-HF study evaluated the treatment effect of AT-001 as an add-on to diabetes standard of care therapies.
    • Approximately 38% of study subjects were on SGLT2 or GLP-1 therapies for treatment of diabetes, while 62% were not.
    • Full study results will be presented at an upcoming medical conference, along with results of the Diabetic Peripheral Neuropathy sub-study, which are still being analyzed.

    Largest study to date of high-dose methotrexate associated acute kidney injury supports the use of Voraxaze® (glucarpidase)

    Retrieved on: 
    Monday, December 11, 2023
    MMSc, Hospital, AKI, Division, Cone Health Women's Hospital, Mortality, Neutropenia, SCR, Society, Odds ratio, Observational study, Acute kidney injury, Transaminase, MPH, Patient, Harvard Medical School, Nursing

    West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX) associated Acute Kidney Injury (AKI) treated with and without glucarpidase.

    Key Points: 
    • West Conshohocken, PA, Dec. 11, 2023 (GLOBE NEWSWIRE) -- BTG Pharmaceuticals, a SERB company, announces the presentation of the largest study to date of patients with high-dose methotrexate (HDMTX) associated Acute Kidney Injury (AKI) treated with and without glucarpidase.
    • Among the 708 patients with HDMTX-AKI, 209 (29.5%) were treated with glucarpidase and 499 (70.5%) were not.
    • Treatment with glucarpidase was associated with a 2.41-fold higher adjusted odds of kidney recovery at hospital discharge (95% CI, 1.33–4.37) compared to those not treated with glucarpidase.
    • “This is the largest study to date of HDMTX-AKI,” said study author Dr. Shruti Gupta, MD, MPH, Director of Onconephrology in the Division of Renal Medicine, Brigham and Women's Hospital.

    Press Release: Sarclisa® (isatuximab) plus KRd significantly improved rate of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma versus KRd alone

    Retrieved on: 
    Monday, December 11, 2023
    Isatuximab, ASCT, ITT, Associate, Bone marrow, EMN, MRD, Young, Multiple myeloma, Society, University of Turin, Lenalidomide, Odds ratio, ASH, University, Dexamethasone, NCAA University Division, AOU, Cell, Patient, Carfilzomib

    The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidation in transplant-eligible patients with newly diagnosed multiple myeloma (MM).

    Key Points: 
    • The Phase 3 trial investigating Sarclisa® (isatuximab) in combination with carfilzomib, lenalidomide and dexamethasone (KRd) showed a statistically significant improvement in the rate of minimal residual disease (MRD) negativity, compared with KRd alone, after autologous stem cell transplant (ASCT) consolidation in transplant-eligible patients with newly diagnosed multiple myeloma (MM).
    • The respective rates of MRD negativity at sensitivity of 10-6 were 67% versus 48% (OR 1.93; p=0.006).
    • There was a statistically significant difference in MRD negativity rates after induction with Sarclisa in combination with KRd versus KRd (10-5: 45% versus 26%, p
    • Effective front-line treatment is critical for newly diagnosed patients, because achieving undetectable levels of disease early in the treatment journey may lead to better long-term outcomes.

    New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation

    Retrieved on: 
    Monday, December 11, 2023
    Biotechnology, Surgery, Health, Pharmaceutical, Health Technology, Odds ratio, Samsung Medical Center, De novo, Blood, OLV, Sungkyunkwan University, Hypoxemia, Risk, MASI, Patient, Multimedia, Journal, FDA, Hyperoxia, Oxygen, Blood gas tension, Perioperative, Ori, Oxygen saturation (medicine), Receiver operating characteristic, Medical device, Medical imaging, Anesthesia, ROC

    ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.

    Key Points: 
    • ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.
    • During anesthesia, ORi was monitored using Masimo RD rainbow SET® Pulse CO-Oximetry sensors, and blood gas analysis was performed 15 minutes after OLV was initiated.
    • Of the 11 potential predictors for PaO2
    • The researchers concluded, “ORi values during one-lung ventilation were significantly correlated with PaO2 measured simultaneously.

    Japan’s First Discovery*1 on Visceral Fat and Immune Activity in Joint Research by Kirin Holdings and Kao

    Retrieved on: 
    Friday, November 24, 2023
    COVID-19, Research, Infectious Diseases, Fitness & Nutrition, Other Health, General Health, University, Health, Science, Education, World Health Organization, Odds ratio, Atherosclerosis, Obesity, Immunity, Coronavirus, Conditional sentence, Ageing, Incidence, Atrophy, WHO, Risk, Journal, Facial muscles, Kirin, Kirin Holdings, Wakayama Medical University, Blood, Vaccine, Pharmaceutical industry, Dietary supplement, PDC, PubMed

    Visceral fat area: Based on a median value of 77 cm2 for all subjects, those with visceral fat less than 77 cm2 were defined as the low visceral fat group, and those with visceral fat greater than 77 cm2 as the high visceral fat group.

    Key Points: 
    • Visceral fat area: Based on a median value of 77 cm2 for all subjects, those with visceral fat less than 77 cm2 were defined as the low visceral fat group, and those with visceral fat greater than 77 cm2 as the high visceral fat group.
    • For the first time in the world, this collaboration found that people with high visceral fat area levels had low pDC activity.
    • It was also suggested that visceral fat area and pDC activity, respectively, affect susceptibility to novel coronavirus infection and influenza, and that people with high visceral fat area and low pDC activity are particularly susceptible to these diseases.
    • Thus, it can be said that it is important for people with high visceral fat area values and low pDC activity to address both visceral fat mass and immune function.

    Late-Breaking Data for Genentech’s BTK Inhibitor Fenebrutinib Show Brain Penetration and Significant Reduction in Lesions in Patients With Relapsing Multiple Sclerosis

    Retrieved on: 
    Friday, October 13, 2023
    Biotechnology, General Health, Health, Pharmaceutical, Clinical Trials, Cerebrospinal fluid, Common, RMS, PPMS, MS, Treatment, Brain, Roche, ROG, Central nervous system, Odds ratio, Great America Committee, Multiple sclerosis, Safety, Disease, Headache, CSF, RO, Research, BTK, Patient, Pharmaceutical industry, Medical imaging, Genentech, Phase

    The late-breaking data were featured in an oral presentation at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis).

    Key Points: 
    • The late-breaking data were featured in an oral presentation at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis).
    • After 12 weeks of continuous treatment, the mean fenebrutinib concentration was 43.1 ng/mL.
    • Thus, the level of fenebrutinib in the brain and central nervous system may conceivably become high enough to reduce MS disease activity and progression.
    • The safety profile of fenebrutinib was consistent with previous and ongoing fenebrutinib clinical trials across more than 2,500 people to date.